Cannabis Science, Inc. (OTCBB: CBIS.OB)
In late December, 2011, Cannabis Science, Inc. (OTCBB: CBIS.OB) reported that CBIS had many serious ailments of which CBIS alerted as part of its ongoing mission to capture the market share. One such alert is Cancer with estimated Global drug sales growth at a compounded annual rate of 12% – 15% reaching $75 to $80 billion by 2012.
Conservatively speaking, if Cannabis Science is able to capture only 1% (one percent) of the Cancer market, it would translate to approximately $75 (seventy five) million in that segment alone.
CBIS is our new penny stock pick and needs to be on the list of penny stocks to watch immediately.
Cannabis Science sales for 2012 are forecasted to be $6,846,000 and has the potential to increase to $65,740,000 in 2014. This sales forecast translates into positive earnings of $.02 per share earnings for 2014.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
Click Here to watch Interview with CEO Robert Melamede, PhD of Cannabis Science, Inc.
|Trading Symbol:||OTCBB: CBIS|
|Total Cash (mrq):||$6,190|
|Shares Outstanding:||241.92 million shares|
|Float:||224.91 million shares|
|Contact Information:||2422 South Trenton Way
Denver, CO 80231
|Investor/Analyst inquiries:||Routh Stock Transfer Inc.
6060 North Dallas Parkway
Plano, Texas 75024
Cannabis Science consults with a number of cancer patients together with several Colorado-licensed dispensaries and physicians. These patients are seeking to become more informed of the current peer-reviewed scientific literature regarding modern and historical use of cannabis preparations for treating cancers. By doing such, patients can make better informed decisions regarding their self-directed cancer treatment.
Cannabis Science has been recorded mentioning that it’s making cannabis-based medicines available to the general public as rapidly as possible. In order to accomplish this, CBIS is taking multiple approaches with its target aim in the United States. The science of cannabinoids has been well known for years but has since exploded over the past decade. Such explosion has laid the scientific foundation for the many medicinal uses of this unique plant.
Cannabinoids are a class of biologically active compounds produced by all vertebrates (endocannabinoids) the Cannabis plant (phytocannabinoids), and more recently patentable synthetic compounds produced by chemists. Today’s modern peer-reviewed science supports the many historical uses that were discovered over thousands of years of medicinal use by herbalists.
Also, Cannabis Science has already released its first two Cannabis Science Brand Formulations, Cannabis Science CT-1 and Cannabis Science MT-1. Both are now available at both Cannabis Therapeutics and Marisol Therapeutics exclusively for Colorado State licensed medical marijuana patients.
If only Cheech and Chong were still together, CBIS would have one hell of a promotion duo with them today. CBIS is our near-term pick and should be see tremendous gains over the coming weeks/months.
AimHighProfits.com strives to provide you with the hottest stock alerts in the market in Real-Time. We focus on stocks that trade for $5 per share or less, some as little as a few pennies with upside potential. Our goal is committed to producing and publishing the highest-quality insight and analysis of small-cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions and to inform you of the best stocks in the market before they move. Our focus is primarily on OTC stocks in the stock market today which have traditionally been ignored by Wall Street.
We have particular expertise with internet stocks, gold stocks, renewable energy stocks, biotech stocks, oil stocks and green energy stocks. There are many hot penny stock opportunities present in the OTC market every day and we seek to exploit these hot stock gains for our members before the average daytrader is made aware of them.
Aim High Profits Disclaimer
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. AimHighProfits.com is a wholly-owned subsidiary of Kelevra Media Innovation.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.Share